OncoCyte Corp reports results for the quarter ended in September - Earnings Summary

Insight Molecular Diagnostics

10/11/2022 23:27

* OncoCyte Corp  OCX.OQ  reported a quarterly adjusted loss
of 8
cents​​ per share for the quarter ended in September. The mean
expectation of six analysts for the quarter was for a loss of 11
cents per share.
    * Revenue rose 3.4% to $1.02 million from a year ago;
analysts
expected $1.48 million. 
    * OncoCyte Corp's reported EPS for the quarter was a loss
of 8
cents​.
    * The mean earnings estimate of analysts had fallen by
about 3% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * OncoCyte Corp shares had fallen by 17.8% this quarter and
lost 72.3% so far this year.
    * The company reported a quarterly loss of $9.33 million.
    * Wall Street's median 12-month price target for OncoCyte
Corp is
$2.30 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 11:27 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.11          -0.08          Beat
 Jun. 30 2022      -0.12          -0.07          Beat
 Mar. 31 2022      -0.12          -0.11          Beat
 Dec. 31 2021      -0.13          -0.12          Beat